Oragenics, Inc. (NYSEAMERICAN:OGEN) Short Interest Update

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totaling 108,196 shares, a drop of 22.3% from the December 15th total of 139,273 shares. Based on an average daily volume of 70,912 shares, the short-interest ratio is currently 1.5 days. Approximately 2.9% of the company’s stock are sold short. Approximately 2.9% of the company’s stock are sold short. Based on an average daily volume of 70,912 shares, the short-interest ratio is currently 1.5 days.

Institutional Investors Weigh In On Oragenics

Large investors have recently bought and sold shares of the business. Bank of America Corp DE lifted its stake in Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after acquiring an additional 15,338 shares during the period. Sabby Management LLC purchased a new position in shares of Oragenics during the third quarter valued at approximately $77,000. Finally, Clear Street LLC bought a new position in Oragenics during the second quarter valued at approximately $270,000. 18.71% of the stock is currently owned by institutional investors.

Oragenics Stock Up 1.4%

Shares of NYSEAMERICAN:OGEN traded up $0.01 on Friday, hitting $0.95. 30,191 shares of the company traded hands, compared to its average volume of 50,174. The company has a market cap of $3.96 million, a PE ratio of -0.08 and a beta of 0.90. The stock has a 50 day simple moving average of $0.91 and a 200-day simple moving average of $1.14. Oragenics has a 52 week low of $0.74 and a 52 week high of $18.90.

Oragenics (NYSEAMERICAN:OGEN) last announced its quarterly earnings data on Friday, November 7th. The company reported ($1.96) earnings per share for the quarter.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.